General Information:

Id: 3,890 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Fatty liver disease, nonalcoholic
Insulin resistance
Metabolic syndrome
Reference: Matikainen N and Taskinen MR(2012) Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes Curr Cardiol Rep 14: 721-731 [PMID: 22941588]

Interaction Information:

Comment Data suggest that dual metabolic defects: 1) overproduction of large VLDL particles driven by liver fat, and 2) impaired catabolism of TRLs due to high apoCIII are needed to produce hypertriglyceridemia in MetS. Therefore, none of the current therapies are optimal to treat residual risk associated with diabetic dyslipidemia as they are not directly addressing these underlying defects. After about 20 years of clinical use of statins, the awareness of diabetogenic potential has raised the debate whether statins are justified or not, especially in the primary prevention in MetS subjects with already compromised glucose metabolism. A large meta-analysis of statin trials confirmed that indeed statin therapy is associated with increased glucose levels and new-onset diabetes. Studies demonstrate a dose-dependent effect, at least with atorvastatin and rosuvastatin.
Formal Description
Interaction-ID: 39328

drug/chemical compound


increases_activity of